<DOC>
	<DOCNO>NCT02371577</DOCNO>
	<brief_summary>This phase 2 study immunomodulatory drug , lenalidomide , evaluate potential beneficial effect immune system patient chronic lymphocytic leukemia ( CLL ) CLL-associated immunodeficiency . 17 patient enrolled CLL , small lymphocytic lymphoma ( SLL ) , monoclonal B-cell lymphocytosis ( MBL ) , measurable immune compromise , iwCLL indication CLL therapy ( ie non-progressive disease ) .</brief_summary>
	<brief_title>Evaluation Immune Restoration Potential Of Lenalidomide</brief_title>
	<detailed_description>This phase 2 study immunomodulatory drug , lenalidomide , evaluate potential beneficial effect immune system patient chronic lymphocytic leukemia ( CLL ) CLL-associated immunodeficiency . 17 patient enrolled CLL , small lymphocytic lymphoma ( SLL ) , monoclonal B-cell lymphocytosis ( MBL ) , measurable immune compromise , iwCLL indication CLL therapy ( ie non-progressive disease ) . Lenalidomide administer orally 21 day 28 day cycle , start 2.5mg dose , dose escalation cycle maximum 25mg absence grade 2 high hematologic non-hematologic adverse event . Treatment duration primary endpoint assessment 6 cycle , though patient restrict continue lenalidomide off-study , clinically indicate</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Main 1 . Clinical phenotypic verification B cell CLL/ SLL/ MBL measurable disease . 2 . Subjects must total serum IgG &lt; 500 mg/dL 3 . Disease Status/ Prior Therapy : There requirement restriction prior therapy . 4 . Recovered toxic effect prior therapy clinical baseline . 5 . Both men woman race ethnic group eligible trial . 6 . Women childbearing potential ( postmenopausal least one year surgically incapable bear child ) must agree become pregnant duration study . Both men woman must agree use barrier method contraception duration study 8 week final dose lenalidomide . 7 . ECOG performance status 02 . 8 . Adequate hematologic function : 8.1 . Platelet count ≥ 50,000/µL ; AND 8.2 . Hemoglobin ≥ 8.0 g/dL 8.3 . Absolute neutrophil count &gt; 1000 /uL 9 . Adequate renal function : 9.1 . Serum creatinine &lt; 1.5 time upper limit normal ; OR 9.2 . Calculated Creatinine clearance ( CrCl ) ≥ 50 mL/min 10 . Adequate hepatic function : 12.1 . Total bilirubin ≤ 2.5 time upper limit normal ; AND 12.2 . ALT ≤ 2.5 time upper limit normal . 11 . Able take aspirin ( 81mg 325mg ) daily , warfarin , low molecular weight heparin , equivalent anticoagulation prophylactic medication . 12 . All study participant must register mandatory Revlimid REMS® program , willing able comply requirement REMS® . 13 . Females childbearing potential must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prior start Revlimid® must either commit continue abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take Revlimid® . Men must agree use latex condom sexual contact FCBP even successful vasectomy . 14 . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program . 1 . Progressive CLL require therapy base 2008 international work group guideline ( iwCLL 2008 , Hallek et al , Blood 2008 ) . 2 . Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event see animal/human study . 3 . Known hypersensitivity thalidomide lenalidomide . 4 . Prior lenalidomideassociated deep vein thrombosis 5 . Deep vein thrombosis superficial thrombophlebitis cause current anticoagulation therapy time screen . 6 . Patients currently receive another investigational agent exclude . 7 . Patients chemotherapy ( e.g. , purine analogue , alkylating agent ) , radiation therapy , tyrosine kinase inhibitor therapy , participation investigational drug treatment within 4 week initiation lenalidomide time study . 8 . Patients prior ( within 8 week initiation lenalidomide ) concurrent antibody therapy direct CLL . 9 . Current infection require parenteral antibiotic . 10 . Known seropositive active viral infection human immunodeficiency virus ( HIV ) ; know active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) base detectable viral load . Patients seropositive hepatitis B virus vaccine eligible . 11 . Active malignancy within previous 2 year ( completely resect nonmelanoma skin cancer carcinoma situ ) . 12 . Known history IgA IgG monoclonal gammopathy undetermined significance ( MGUS ) 13 . Known central nervous system ( CNS ) involvement malignancy . 14 . Untreated autoimmunity autoimmune hemolytic anemia , immune thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Revlimid</keyword>
</DOC>